Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials

Medicine & Life Sciences

• semaglutide 100%
• Type 2 Diabetes Mellitus 43%
• Safety 33%
• Food 10%
• Therapeutics 9%
• Incretins 9%
• Glucagon-Like Peptide-1 Receptor 9%
• Phase III Clinical Trials 8%
• Craving 8%
• Risk Management 7%
• Appetite 7%
• Glucagon 7%
• Diabetes Complications 7%
• Energy Intake 7%
• Islets of Langerhans 7%
• Standard of Care 6%
• LDL Cholesterol 6%
• Blood Glucose 5%
• Weight Loss 5%
• Cardiovascular Diseases 5%
• Body Weight 5%
• Placebos 4%
• Insulin 4%
• Clinical Trials 4%
• Guidelines 4%
• Blood Pressure 4%